BRAUN
25.8.2021 11:02:05 CEST | Business Wire | Press release
Braun today officially announced the judging panel for the 21st BraunPrize; an international design competition that aims to promote the work of young designers, creatives and inventors, every three years.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210825005057/en/
Established in 1968, the historic BraunPrize was Germany’s first international competition and its commitment to nurturing young talent has been highly regarded by the design world and the design-aware public ever since.
This year, young, up-and-coming designers and inventors have been tasked to help ‘Shape Tomorrow’ – a call to action to explore good design that will address and solve the challenges of today and tomorrow.
The judging panel for this prestigious prize includes internationally renowned experts who will honor visionary ideas and clever solutions that will help promote behavioural change and make an impact on today’s society and the future of the planet with $100,000 USD. The winning submissions will be recognised and awarded by the jurors at a virtual awards ceremony in November.
The 21st edition of the BraunPrize is set to exceed the last competition held in 2018, which received 3,087 entrants from 107 counties.
The judges for the 2021 BraunPrize are:
- Virgil Abloh, Chief Creative Director and founder of Off-White ™ and Men’s Artistic Director at Louis Vuitton (USA)
- Cecilie Manz, Designer and founder of Cecilie Manz Studio (Denmark)
- Johanna Schoemaker, Former BraunPrize Winner and owner of sustainable jewellery brand Quite Quiet (Germany)
- Li Ningning, Director of Industrial Design across the Xiaomi Ecosystem (China)
- Sukwoo Lee, Founder of SWNA (South Korea)
- Gary Hustwit, Filmmaker, and visual artist based in New York (USA)
- Stefan Schamberg, Vice President R&D, Grooming Braun and Devices (Germany)
- Prof. Oliver Grabes, Head of Design at Braun and Chairman of the BraunPrize (Germany)
Prof. Oliver Grabes said: “It was important that this year’s competition reflects the international and digital-first nature of the world we live in today. We’re excited to have assembled a diverse group of some of the most talented creative leaders from across the globe. It is a privilege to have their expertise to judge and award the wonderful talent that will emerge from the competition.”
Stefan Schamberg said; “When I began my career as a design engineer I was fortunate enough to take my early steps into the industry with Braun, a brand that always stands for good design, functionality and sustainable long-lastingness. The BraunPrize provides the next generation with a similar opportunity to showcase their creativity and the scope of their imagination to produce concepts that could change the world. It will be exciting to see what this young talent will produce.”
Virgil Abloh said; “As with any industry, it’s important that we nurture young up and coming talent that will continually push the boundaries of what is possible creatively. It’s an honour to be a part of a judging panel as we play our own part in helping the next generation of creatives and innovators.”
Cecilie Manz , said; “For me, encouragement of the next generation of designers is crucial.
Gary Hustwit said; “I’ve been a fan of Braun for many years, and it’s a privilege to be part of this year’s jury panel. I had the opportunity to do a deep dive into the company’s design history during my research for the film I made about Dieter Rams. The BraunPrize has an important lineage and continues to be a fantastic platform to showcase and nurture young creatives in the design industry and beyond. I’m excited to be part of this initiative and I’m really looking forward to seeing some groundbreaking new ideas.”
Li Ningning , said; “Good design is far more than designing products that are aesthetically pleasing - good design has the power to improve and change the world by thinking from the original point of the projects. The challenge Shape Tomorrow is a fantastic opportunity for young designers to address and provide solutions to several global issues we are facing”.
Sukwoo Lee , said; “It is an honour to be part of the jury for such a meaningful and important award. Whilst studying for my university degree, I was inspired by many of the BraunPrize winning submissions and I have closely followed the work of Braun and Dieter Rams throughout my career. I’m excited to see what this year’s competition will bring.”
Johanna Schoemaker said; “I was fortunate enough to have been part of the BraunPrize experience and know first-hand the impact that winning can have on a young designer’s career. I’m very excited to be joining as a judge this year, and to see what great design concepts we receive that could help to improve and change the world we live in for the better.”
The 2021 BraunPrize International Design Competition is open globally and is free to enter. Submissions are welcome from young designers and inventors with less than 5 years work experience and students of any profession.
For my information on the 2021 BraunPrize Jury Panel and the competition please visit www.braunprize.org
-----ENDS-----
Notes to editors:
Photo credits:
- Virgil Abloh - Richard Anderson
- Cecilie Manz - Casper Sejersen
- Johanna Schoemaker - Lina Zangers
- Sukwoo Lee - designpress
- Gary Hustwit by Ebru Yildiz
About the Braun Prize:
- The Braun Prize was established in 1968
- The Braun Prize 2021 marks the 21st edition of the international design competition
- In 2018, the Braun Prize received 3,087 entries from 107 countries
- The Braun Prize 2021 is organized by Braun, a Procter & Gamble brand, and managed by the Braun Design Team in Kronberg, Germany
About Braun:
- Braun, a subsidiary of Procter & Gamble founded in Germany in 1921, develops and manufactures a wide variety of small domestic appliances that marry technical innovation, reliable quality, and distinctive design. These range from electric shavers and beauty products to hair care appliances. Braun products enjoy worldwide distribution. Please visit www.braun.com for the latest news and in-depth information about the Braun brand.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210825005057/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
